Search

Search Constraints

You searched for: Author/Creator Guidi, Luisa

Search Results

21. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. (2nd January 2021)

22. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Issue 3 (18th August 2018)

23. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Issue 3 (21st February 2019)

24. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Issue 2 (13th January 2017)

25. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Issue 2 (13th January 2017)

26. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Issue 2 (February 2017)

28. TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade. Issue 10 (October 2020)